Title:Comparing the Efficacy and Safety of Nebulized Gentamicin Plus Amikacin
versus Tobramycin in Patients with Cystic Fibrosis
Volume: 19
Issue: 1
Author(s): Fatemeh Kouhestani, Maryam Hassanzad*Shadi Baniasadi*
Affiliation:
- Pediatric Respiratory Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran
- Tracheal Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran
Keywords:
Cystic fibrosis, gentamicin, tobramycin, FEV1, FVC, Pseudomonas aeruginosa.
Abstract:
Background: Cystic fibrosis is an autosomal recessive disease that causes respiratory
tract infection. These patients use nebulized antibiotics such as tobramycin and gentamicin plus
amikacin. Due to the high price of tobramycin and the inaccessibility of this drug in Iran at different
periods, we aimed to compare the efficacy and safety of nebulized plus amikacin and tobramycin
in patients with cystic fibrosis.
Methods: In this analytic cross-sectional study, data were collected from the records of all patients with
cystic fibrosis. They were divided into two groups by their type of nebulized antibiotic. Group 1 included
41 patients who received 80 mg gentamicin and 500 mg amikacin as a nebulized antibiotic every other
month, whereas, group 2 consisted of 9 patients who received 300 mg nebulized tobramycin. Collected
data were pulmonary function parameters, body mass index, the frequency of hospitalization, infection
progress, Shwachman-Kulczycki score, and renal complications. The data were compared in terms of
efficacy and renal adverse effects by independent t-test and repeated measure ANOVA.
Results: A total of 50 cystic fibrosis patients were evaluated and there was no significant difference
between group 1 and group 2 in terms of pulmonary function, frequency of hospitalizations,
body mass index, Shwachman-Kulczycki score, infection progress, and renal complications. Notably,
pulmonary function factors were reduced in both groups over time during their treatment.
Conclusion: Nebulized tobramycin and gentamicin plus amikacin had similar efficacy against
Pseudomonas aeruginosa in cystic fibrosis and had no serious renal complications.
